ASX 200 Stocks May Surge 30% to 75%

Rowan Ashford

Published: February 8, 2026 4:34 PM ET

The ASX 200 stocks are being spotlighted for their potential growth, with analysts forecasting a significant increase in value. Expert evaluations suggest that specific shares could surge between 30% and 75% over the next year. This makes them appealing candidates for investors seeking substantial market returns.

Potential Growth in ASX 200 Stocks

Among the highlighted companies is Neuren Pharmaceuticals Ltd (ASX: NEU). Analysts from Bell Potter have reaffirmed a buy rating, setting a price target of $22.00. Currently trading at $12.52, this indicates a remarkable upside potential of 75% within the next 12 months.

Challenges and Opportunities for Neuren Pharmaceuticals

Despite recent approval delays in Europe, the outlook remains optimistic. Bell Potter acknowledges these setbacks but still sees considerable value in NEU. The firm’s analysis indicates:

Reduced probability of success assumption for EU approval of Daybue.
Projected first EU sales have been pushed to calendar year 2027.
The Phase 3 trial for NNZ-2591 is approximately 18 months away from results.

With an estimated A$65 million in royalties from Daybue sales in the U.S. by 2026, NEU’s financial position is expected to remain strong.

Pinnacle Investment Management Group Ltd (ASX: PNI)

Another promising investment identified is Pinnacle Investment Management Group Ltd (ASX: PNI). Following underwhelming half-year results, analysts at Morgans have upgraded their rating to a buy. They have set a price target of $23.21, which implies a 33% upside from the current price of $17.49.

Financial Insights for Pinnacle Investment Management

Morgans’ analysis of PNI reveals several positive factors despite a headline miss:

NPAT for the first half of 2026 was approximately A$67 million, down 11% from the prior corresponding period.
The results were largely influenced by one-off adjustments, making the overall financial picture stronger than it appears.
Projections for FY27 have improved by 8% due to anticipated earnings benefits.

Investors should consider these insights into PNI as they point to possible recovery and growth moving forward.

Conclusion

The ASX 200 stocks, particularly Neuren Pharmaceuticals and Pinnacle Investment Management, present potentially lucrative opportunities. With analysts forecasting possible surges of 30% to 75%, investors may want to explore adding these shares to their portfolios.